Abstract

Pericardial synovial sarcoma is an extremely rare tumor with poor prognosis. Timely diagnosis and aggressive multimodal management improves patient outcome. We present our experience of diagnosis and management of a young patient with monophasic synovial sarcoma arising from pericardium.A 27-year-old man presented with dyspnea and cough of three weeks duration. Examination revealed sinus tachycardia, distant heart sounds and elevated jugular venous pressure. Chest X-ray showed widened mediastinum. Transthoracic echocardiogram (TTE) noted large pericardial effusion with tamponade physiology. Therapeutic pericardiocentesis yielded hemorrhagic fluid. Computed tomography (CT) of the chest showed persistent pericardial effusion and a left anterior mediastinal mass. Left anterior thoracotomy, pericardial window and left anterior mediastinotomy were done, revealing a well-encapsulated gelatinous tumor originating from the pericardium. Histology and immunohistochemical profile showed the tumor to be a monophasic synovial sarcoma. Fluorescent in-situ hybridization (FISH) was positive for SS18 (SYT) gene rearrangement on chromosome 18q11, substantiating the diagnosis. Work-up for metastases was negative. Neo-adjuvant chemotherapy with high dose ifosfamide led to substantial reduction in the size of the tumor. The patient underwent surgical resection and external beam radiation therapy (EBRT) post surgery. He had symptom-free survival for 8 months prior to local recurrence. This was managed with left lung upper lobectomy and follow-up chemotherapy with docetaxel. The patient is currently stable with an acceptable functional status.In patients with pericardial effusions of unknown etiology, multiple modalities of cardiac imaging must be employed if there is suspicion of a pericardial mass. CT and magnetic resonance imaging (MRI) are useful to evaluate for pericardial thickening or masses in addition to TTE. Treatment of synovial sarcoma is not well established. Surgery is the cornerstone of treatment. In non-resectable tumors, aggressive neo-adjuvant chemotherapy with ifosfamide followed by surgical resection and EBRT may lead to improved outcome.

Highlights

  • Pericardial synovial sarcoma is an extremely rare tumor with poor prognosis

  • Surgery is the cornerstone of treatment of this tumor, we used multiple modalities of treatment such as neo-adjuvant chemotherapy using high-dose ifosfamide and external beam radiation therapy (EBRT)

  • Our patient was treated with docetaxel for his local recurrence based on evidence showing that docetaxel is an efficacious and tolerable treatment as rescue medication in ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma[23]. This case report describes a case of monophasic synovial sarcoma of pericardial origin presenting as pericardial effusion with cardiac tamponade physiology in a young man

Read more

Summary

Introduction

Synovial sarcomas are malignant soft tissue tumors in extremities with a predilection for juxta-articular location and are predominantly diagnosed in young adults. To the authors’ knowledge, only 20 cases of synovial sarcomas originating from the pericardium have been described in the English literature to date[2] This type of tumor is known to have a poor prognosis with no clarity about the best approach in managing this disease. On repeat CT imaging prior to planned surgical excision, the tumor had substantially decreased in size (> 50%) and the patient was noted to have elevation of left hemi-diaphragm indicating likely involvement of the left phrenic nerve. The resected mediastinal mass (6.5 × 4 × 3 cm) was confirmed to be a monophasic synovial sarcoma on histology and immunohistochemistry. The patient was noted to have an anterior mediastinal mass extending to the left upper lobe of the lung and a left pleural effusion.

Discussion
Findings
Conclusions
Demmy TL
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call